Baker Bros. Advisors 13F: Exits RARE Stake

Baker Bros. Advisors has closed out its position in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), according to the firm's latest Form 13F filing with the SEC. The investment firm sold all 2,772,692 shares it previously held. The transaction was reported in the regulatory filing for the period ending May 15, 2026.

Baker Bros. Advisors Closes the Book on Ultragenyx

Before this transaction, the investment fund held 2,772,692 shares of the biotechnology firm. By parting with all of those shares, Baker Bros. Advisors reduced its position by exactly 100.0%. Because 13F filings are backward-looking and show holdings as of a specific date, this reporting may not represent the fund's current investment strategy or active portfolio.

Ultragenyx Stock Performance and Valuation

On Sunday, shares of Ultragenyx were priced at $33.39. The stock has shown upward momentum since the filing period closed, trading closer to its 52-week high of $39.89 than its 52-week low of $12.73. The biotech company's 50-day moving average sits at $23.86, and its 200-day moving average is $25.05. Ultragenyx has a forward P/E ratio of 21.6479, but it does not have a trailing P/E ratio because the company is not currently profitable.

Recent Earnings and Revenue Growth

In its latest financial updates, Ultragenyx reported annual revenue of $717.0 million. This represents a solid revenue growth rate of 28.1% year-over-year. However, the company posted earnings per share of -$5.83, alongside a negative net margin of -81.73%. Investors are looking toward November 3, 2026, when the company is scheduled to deliver its next quarterly earnings report.

Executive Officers and Insiders Trim Positions

Corporate insiders at Ultragenyx have also engaged in some moderate selling. On June 15, 2026, Karah Herdman Parschauer, the Executive Vice President and Chief Legal Officer, sold 1,899 shares of stock at an average price of $24.62, totaling $46,753.38. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. On that same day, insider Corsee Sanders sold 2,000 shares of the company at an average price of $25.05, resulting in a total transaction value of $50,100.00.

Wall Street Analysts Lift Price Targets

Several research firms updated their expectations for Ultragenyx in September 2026. On September 21, 2026, Evercore ISI Group kept an In-Line rating but bumped its price target to $18.0 from $16.0. Barclays maintained its Overweight rating on the same day, raising its target to $35.0 from $32.0. Earlier, on September 18, 2026, Cantor Fitzgerald kept an Overweight rating and pushed its target to $39.0, while Canaccord Genuity maintained a Buy rating with a $39.0 target. Goldman Sachs took a more cautious stance on September 4, 2026, maintaining a Neutral rating with a $19.0 target. Across 19 analyst opinions, the consensus recommendation for the stock is a buy, with an average price target of $28.05.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical is a California-based biotechnology business focused on discovering and commercializing treatments for rare and ultra-rare genetic diseases. The company's portfolio includes therapies for bone disorders, metabolic diseases, and rare lysosomal storage conditions. Finding successful treatments in this niche market is highly complex, making institutional backing and insider sentiment key indicators for regular investors.

What to Watch at Ultragenyx Pharmaceutical Inc.

As the biotech sector experiences shifting dynamics, investors should monitor how other institutional funds handled Ultragenyx shares during the same period when those filings become public. The company's upcoming earnings release on November 3, 2026, will also provide fresh data on whether its revenue growth can help narrow its net losses.